gdc
FDA Approvals, News & Updates

Recent FDA Drug Approvals: A Directory for Patients

January 2021 – A Patient Guide to Recent FDA-Approved Oncology Drugs

Bladder Cancer

Keytruda (key-true-duh)

Keytruda is a medicine that may treat certain cancers by working with your immune system. It is also known by its generic name, pembrolizumab, and is given to patients through an intravenous (IV) injection.

Keytruda was first approved by the FDA in 2014 to treat a type of skin cancer called melanoma. It has since received many additional approvals to treat other types of cancer, such as lung cancer, lymphoma, esophageal cancer, among others.

In January 2020, Keytruda received an additional approval to treat Bacillus Calmette-Guérin–unresponsive, high-risk, nonmuscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, in patients who are ineligible for or have elected not to undergo cystectomy.

Merck, the maker of Keytruda, offers the Merck Access Program. If you need information or help paying for Keytruda, you can contact the Merck Access Program at 1-855-257-3932 (or 1-855-257-7332 for the hearing impaired). They also offer the KEY+YOU patient support program. You can sign up at www.keytruda.com/key-you-sign-up or call 1-855-398-7832.

For more information, you can visit www.Keytruda.com.

Breast Cancer

Keytruda (key-true-duh)

Keytruda is a medicine that may treat certain cancers by working with your immune system. It is also known by its generic name, pembrolizumab, and is given to patients through an intravenous (IV) injection.

Keytruda was first approved by the FDA in 2014 to treat a type of skin cancer called melanoma. It has since received many additional approvals to treat other types of cancer, such as lung cancer, lymphoma, esophageal cancer, among others.

In November 2020, Keytruda received an additional approval in combination with chemotherapy to treat patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-approved test.

Merck, the maker of Keytruda, offers the Merck Access Program. If you need information or help paying for Keytruda, you can contact the Merck Access Program at 1-855-257-3932 (or 1-855-257-7332 for the hearing impaired). They also offer the KEY+YOU patient support program. You can sign up at www.keytruda.com/key-you-sign-up or call 1-855-398-7832.

For more information, visit www.Keytruda.com.

Margenza (mar-gen-zuh)

Margenza is a HER2/neu receptor antagonist used in combination with chemotherapy for the treatment of adult patients with metastatic HER2- positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least 1 of which was for metastatic disease.

Margenza received FDA approval in December 2020. MacroGenics, the maker of Margenza, anticipates that the drug will be available to patients beginning in March 2021.

To learn more, you can sign up for e-mail updates on the Margenza website at www.margenza.com.

Nerlynx (ner-links)

Nerlynx is a medicine that was originally approved to treat adults with early-stage HER2-

positive breast cancer AND who have previously been treated with trastuzumab-based therapy. It is also known by its generic name, neratinib, and is given to patients as an oral medicine in the form of pills that they can take at home.

Most recently, the FDA approved Nerlynx as treatment in combination with capecitabine (a chemotherapy) for advanced or metastatic HER2-positive breast cancer in adults after having received 2 or more anti–HER2-based regimens for patients with metastatic disease.

Puma Biotechnology, the maker of Nerlynx, offers a mentor program to connect patients who are considering or are already on Nerlynx with someone who is currently taking or has taken Nerlynx. You can find this and other information at www.nerlynx.com.

Trodelvy (tro-dell-vee)

Trodelvy was approved in April 2020 for adult patients with triple-negative breast cancer that has spread outside of the breast to other parts of the body (also called metastatic). To receive treatment with this drug, patients must have received at least 2 prior therapies for metastatic disease.

Trodelvy, also known by its generic name sacituzumab govitecan-hziy, is given to patients through an intravenous (IV) injection. Immunomedics, the maker of Trodelvy, offers Trodelvy Access Services, which is a patient access and reimbursement support program. This program will help you understand specific coverage and reimbursement guidelines. For more information, you can visit trodelvy.com/patient/access-services or call 1-844-TRODELVY (1-844-876-3358).

Tukysa (too-KYE-sah)

Tukysa is a prescription medicine used in combination with the medicines trastuzumab and capecitabine to treat adults with HER2-positive breast cancer that has spread to other parts of the body (metastatic) or that cannot be removed by surgery, and who have received 1 or more anti- HER2 breast cancer treatments.

Tukysa, also known by its generic name tucatinib, is a pill you can take at home. In most cases, your prescription will be filled either through a specialty pharmacy that will mail your pills to your home, or there may be a pharmacy at your healthcare provider’s office or hospital where you can fill your prescription.

Seattle Genetics, the maker of Tukysa, offers a patient assistance and reimbursement support program called Seagen Secure. To learn more, you can visit SeagenSecure.com or call 1-855-4-SECURE.

Seattle Genetics also hosts the Tukysa Ambassador Program where you can share your story and connect with, encourage, and inspire others. To learn more about this program, you can e-mail This email address is being protected from spambots. You need JavaScript enabled to view it. or call 1-888-203-7601.

Colon Cancer

Braftovi (braf-TOE-vee)

Braftovi is a prescription medicine used in combination with a medicine called cetuximab for the treatment of adults with cancer of the colon or rectum (colorectal cancer) that has been previously treated and has spread to other parts of the body, and has a certain type of abnormal BRAF gene.

Braftovi should not be used to treat people with “wild-type” BRAF colorectal cancer. Your healthcare provider will perform a test to make sure that Braftovi is right for you.

Braftovi, also known by its generic name encorafenib, is an oral medication made by Pfizer, Inc. Pfizer offers personalized patient support through their Pfizer Oncology Together program. At Pfizer Oncology Together, they can help you identify financial assistance options so you can get your prescribed Braftovi. They can also connect you with one of their Care Champions who has social work experience and will offer resources that may help with some of your day-to-day challenges. To learn more, visit www.PfizerOncologyTogether.com or call 1-877-744-5675.

Keytruda (key-true-duh)

Keytruda is a medicine that may treat certain cancers by working with your immune system. It is also known by its generic name, pembrolizumab, and is given to patients through an intravenous (IV) injection.

Keytruda was first approved by the FDA in 2014 to treat a type of skin cancer called melanoma. It has since received many additional approvals to treat other types of cancer, such as lung cancer, lymphoma, esophageal cancer, among others.

In June 2020, Keytruda received an additional approval for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Merck, the maker of Keytruda, offers the Merck Access Program. If you need information or help paying for Keytruda, you can contact the Merck Access Program at 1-855-257-3932 (or 1-855-257-7332 for the hearing impaired). They also offer the KEY+YOU patient support program. You can sign up at www.keytruda.com/key-you-sign-up or call 1-855-398-7832.

For more information, visit www.Keytruda.com.

Cutaneous Squamous-Cell Carcinoma

Keytruda (key-true-duh)

Keytruda is a medicine that may treat certain cancers by working with your immune system. It is also known by its generic name, pembrolizumab, and is given to patients through an intravenous (IV) injection.

Keytruda was first approved by the FDA in 2014 to treat a type of skin cancer called melanoma. It has since received many additional approvals to treat other types of cancer, such as lung cancer, lymphoma, esophageal cancer, among others.

In June 2020, Keytruda received an additional approval for patients with recurrent or metastatic cutaneous squamous-cell carcinoma (cSCC) that is not curable by surgery or radiation.

Merck, the maker of Keytruda, offers the Merck Access Program. If you need information or help paying for Keytruda, you can contact the Merck Access Program at 1-855-257-3932 (or 1-855-257-7332 for the hearing impaired). They also offer the KEY+YOU patient support program. You can sign up at www.keytruda.com/key-you-sign-up or call 1-855-398-7832.

For more information, visit www.Keytruda.com.

Esophageal Cancer

Opdivo (op-DEE-voh)

Opdivo, a prescription medicine also known by the generic name nivolumab, is an intravenous (IV) injection made by Bristol Myers Squibb. It is an immunotherapy treatment that works with the T-cells of your immune system and is used to treat many types of cancer, including melanoma, lung cancer, and colorectal cancer, to name just a few.

In 2020, Opdivo received FDA approval to treat people who have cancer of the tube that connects the throat to the stomach (esophageal cancer). To be a candidate for this treatment, the cancer needs to be a type called squamous-cell carcinoma that cannot be removed with surgery and has come back or spread to other parts of the body after treatment with chemotherapy that contains fluoropyrimidine and platinum.

Bristol Myers Squibb offers a patient and caregiver support program called OPDIVO with You. OPDIVO with You is there to help you better understand Opdivo, whether you or a loved one are considering or are already receiving Opdivo. This complimentary program includes helpful information, details about support and advocacy groups, and a Care Counselor as close as your phone. Call 1-855-OPDIVO-1 or visit www.opdivo.com to learn more.

Gastrointestinal Cancer

Ayvakit (aye-vah-kit)

Ayvakit is a prescription medicine used to treat adults with a certain type of stomach, bowel, or esophagus cancer called gastrointestinal stromal tumor (GIST) that cannot be treated with surgery or that has spread to other parts of the body (metastatic), and that is caused by certain abnormal platelet-derived growth factor receptor alpha (PDGFRA) genes. Your healthcare provider will perform a test to make sure that you have this abnormal PDGFRA gene, and that Ayvakit is right for you.

Ayvakit, also known by the generic name avapritinib, is an oral medication made by Blueprint Medicines. Blueprint Medicines offers the patient support program called YourBlueprint, which is designed to assist you throughout your treatment with Ayvakit by providing one-on-one support, financial assistance options, and helpful resources. For more information, visit www.ayvakit.com or call 1-888-BLUPRNT (1-888-258-7768).

To learn more about Ayvakit, visit www.ayvakit.com.

Pemazyre (pemah-zeer)

Pemazyre is made by Incyte and is the first and only FDA-approved prescription medicine that is used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery and who have already received a previous treatment, and whose tumor has a certain type of abnormal FGFR2 gene. Your healthcare provider will test the cancer for a certain type of abnormal FGFR2 gene and make sure that Pemazyre is right for you.

Pemazyre, also known by its generic name pemigatinib, is an oral medication you take daily at home. Incyte provides a downloadable treatment tracker to help you keep track of which days you need to take a Pemazyre tablet, and which days you do not. They also offer a patient support program called IncyteCARES for PEMAZYRE that will help you get started with your medicine and provide information and resources throughout your treatment. To learn more, visit IncyteCARES.com or call 1-855-452-5234.

For more information about Pemazyre, visit www.pemazyre.com.

Qinlock (kin-lok)

Qinlock is a prescription medicine used to treat adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST. Qinlock is not a chemotherapy. It is a medicine called a tyrosine kinase inhibitor that patients take in the form of an oral tablet.

Qinlock, also known by its generic name ripretinib, is made by Deciphera Pharmaceuticals. Deciphera offers support services to patients on their website. Patients can sign up to receive additional information about Qinlock by visiting the Deciphera-supported site www.gisttogether.com. You can also request help with insurance issues or cost concerns through Deciphera’s AccessPoint program or by calling 1‑833‑4DACCES (1‑833‑432‑2237), Monday- Friday, 8 am - 8 pm ET.

Visit www.qinlock.com to learn more.

Leukemia/Lymphoma

Imbruvica (im-BRU-vih-kuh)

Imbruvica, also known by its generic name ibrutinib, was approved by the FDA in April 2020 as a first-line treatment in combination with rituximab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Imbruvica is an oral medication you have the freedom to take at home, or wherever you may be.

This drug has previously been approved for the treatment of adults with other types of leukemias and lymphomas.

The makers of Imbruvica offer the YOU&i Support Program to help answer some of your questions about the financial aspects of taking Imbruvica. You can also visit the Imbruvica website to sign up for e-mails about treatment, and also receive a free guide to help you have better conversations with your doctor. To learn more, visit www.imbruvica.com.

Monjuvi (mon-JOO-vee)

Monjuvi is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), and who cannot receive a stem cell transplant.

Monjuvi, also known by its generic name tafasitamab-cxix, is given to patients as an intravenous (IV) infusion into one of your veins at a clinic or infusion center.

Monjuvi is the result of a collaboration between MorphoSys US Inc and Incyte Corporation—2 companies that are committed to helping patients who are prescribed Monjuvi through the My Mission Support program. This program offers patient access and support services to eligible patients and caregivers. For personalized support from a My Mission Support Program Specialist, call 1-855-421-6172, Monday-Friday, 8 am - 8 pm ET, or visit www.MyMISSIONSupport.com to learn more.

To learn more about Monjuvi, you can visit www.monjuvi.com.

Tazverik (taz-vayr-ik)

Tazverik is a prescription medicine used to treat adults with follicular lymphoma when the disease has come back (relapsed) or did not respond to treatment, whose tumors have an abnormal EZH2 gene as determined by an FDA-approved test, and who have been treated with at least 2 prior medicines. It was also approved to treat adults with follicular lymphoma when the disease has relapsed or did not respond to treatment, and for patients who have no other satisfactory treatment options.

Tazverik, also known by its generic name tazemetostat, was also recently approved to treat epithelioid sarcoma.

Tazverik is made by Epizyme, which offers EpizymeNOW Patient & Product Support programs. EpizymeNOW offers a Quick Start Program, the Bridge Supply Program, the Patient Assistance Program, and the Co-Pay Assistance Program. To learn more about these services, ask your doctor or contact EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday-Friday, 9 am - 6 pm ET.

To learn more about Tazverik, please visit www.tazverik.com.

Tecartus (tek-ahr-thus)

Tectarus is the first and only FDA-approved CAR T-cell therapy for adult patients with relapsed or refractory mantle cell lymphoma. Tecartus is different than other cancer medicines because it is made from the patient’s own white blood cells, which are modified to recognize and attack lymphoma cells.

Tecartus is available only through a Risk Evaluation and Mitigation Strategy (REMS) program to ensure that the benefits of Tecartus outweigh the risks of cytokine release syndrome (CRS) and neurologic toxicities. For more information about this REMS program, please visit www.yescartatecartusrems.com or call 1-844-454-KITE (5483), Monday- Friday, 5 am - 6 pm PT.

For more information, please visit www.tecartus.com.

Xpovio (x-PO-vee-O)

Xpovio, also known by its generic name selinexor, is an oral prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who have received at least 2 prior therapies. It was also recently approved to treat multiple myeloma.

Karyopharm Therapeutics, the maker of Xpovio, offers the KaryForward patient support program that provides assistance and resources to patients and caregivers. From insurance coverage and financial assistance to support and resources, KaryForward will help you every step of the way. To get started, download an enrollment form at www.karyforward.com, or call 1-877-KARY4WD (1-877-527-9493), Monday-Friday, 8 am - 8 pm ET.

To learn more, please visit www.xpovio.com.

Liver Cancer

Opdivo (op-DEE-voh) plus Yervoy (yur-voi)

Opdivo plus Yervoy was approved in March 2020 for people who have liver cancer (also called hepatocellular carcinoma) and who have previously received treatment with sorafenib. It is given to patients through an intravenous (IV) injection.

This drug combination, also known by their generic names nivolumab and ipilimumab, has been previously approved to treat special types of melanoma, advanced kidney cancer, and metastatic colorectal cancer that progressed after chemotherapy.

Opdivo plus Yervoy also received approvals in 2020 for certain subsets of patients with non–small-cell lung cancer.

Bristol Myers Squibb, the maker of both of these drugs, offers the BMS Access Support program, which provides resources to help patients understand their insurance coverage and find information on sources of financial support, including copay assistance for eligible commercially insured patients. For more information, ask your doctor, visit www.bmsaccesssupport.com, or call BMS Access Support at 1-800-861-0048, Monday-Friday 8 am - 8 pm ET.

On the website for Opdivo, you will also find helpful patient and caregiver support materials, such as a pocket guide for Opdivo + Yervoy and a side effect tracker. For these and more resources, visit www.opdivo.com.

Tecentriq (te-SEN-trik)

Tecentriq was approved by the FDA in May 2020 to treat a type of liver cancer (also known as hepatocellular carcinoma) in combination with a drug called Avastin (also known by the generic name bevacizumab) when the cancer has spread or cannot be removed by surgery and you have not received other medicines by mouth or injection through your vein (IV) to treat the cancer.

Tecentriq has been previously approved to treat several types of cancer, including non–small-cell lung cancer, small-cell lung cancer, urothelial cancer, and triple-negative breast cancer.

Tecentriq, also known by its generic name atezolizumab, is made by Genentech and is given to patients through an intravenous (IV) infusion. On the Tecentriq website, Genentech offers a patient assistance tool to help you find out which financial assistance option might be right for you. You will also find tips for preparing for potential side effects and making the most of your doctor visits. To learn more, visit www.tecentriq.com.

Lung Cancer

Alunbrig (uh-lun-brig)

Alunbrig, also known by its generic name brigatinib, is a prescription medicine used to treat adults with non–small-cell lung cancer (NSCLC) that have a certain abnormal ALK gene that has spread to other parts of the body. The FDA approved this drug in May 2020 as a first-line treatment of patients with NSCLC and ALK mutation, as detected by an FDA-approved test.

Alunbrig was previously used as treatment of patients with NSCLC and ALK mutation after treatment with a drug called Xalkori (also known by its generic name crizotinib).

Alunbrig is an oral medication made by Takeda Oncology. Takeda offers the Here2Assist patient support program that can help connect you with possible financial assistance and additional resources. You can learn more by calling 1-844-817-6468 or visiting www.Here2Assist.com. You can also visit www.alunbrig.com to obtain the patient brochure and other useful information.

Cyramza (sigh-ram-zuh)

Cyramza is a prescription medicine used to treat certain types of cancer. It is given by intravenous (IV) infusion. An IV infusion is when a needle is placed into your vein and a medicine is given slowly.

In May 2020 the FDA approved Cyramza as a first-line treatment in combination with erlotinib of EGFR mutation–positive non–small-cell lung cancer (NSCLC) that has spread in the body (metastatic). It has been previously approved for the treatment of advanced or metastastic gastric or gastroesophageal junction adenocarcinoma; treatment, in combination with docetaxel, of metastatic NSCLC progressing during or after chemotherapy; and treatment of metastatic colorectal cancer.

Cyramza, also known by its generic name ramucirumab, is made by Eli Lilly, which offers the Lilly Oncology Support Center for patients. They strive to offer reliable and individualized treatment support for eligible patients prescribed a Lilly Oncology product whether they are insured, underinsured, or simply uninsured. Services include help with benefit verification, prior authorization, paying for medicine, and specialty pharmacy coordination. To learn more, you can call the support center at 1-866-472-8663, Monday-Friday, 8 am - 10 pm ET, or visit www.LillyOncologySupportCenter.com.

For additional information and resources related to Cyramza, please visit www.cyramza.com.

Gavreto (gav-reh-toh)

Gavreto is a drug used to treat adult patients with non–small-cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) and is caused by abnormal RET genes. Gavreto also recently received an additional FDA approval for use in patients with RET-positive advanced thyroid cancer.

To see if your lung cancer is RET-positive, your doctor will need to perform a type of test called a biomarker test. A biomarker test can help your doctor decide if Gavreto could be right for you.

Gavreto, also known by its generic name pralsetinib, is a once-daily oral prescription medicine.

The maker of Gavreto, Blueprint Medicines, offers the YourBlueprint patient support program. This program is designed to assist you throughout your treatment with Gavreto by providing financial assistance, temporary treatment programs, and a dedicated case manager. Learn more about the YourBlueprint program by calling 1-888-BLUPRNT (1-888-258-7768) or visiting www.YourBlueprint.com.

To learn more about Gavreto, visit www.gavreto.com.

Imfinzi (im-FIN-zee)

Imfinzi, also known as durvalumab, is a prescription medicine that was approved in March 2020 to treat adults with a type of lung cancer called small-cell lung cancer (SCLC). Imfinzi is an immunotherapy that may be used with the chemotherapy medicines etoposide and carboplatin or cisplatin as your first treatment when the SCLC has spread within your lungs or to other parts of the body.

This drug has previously been approved for non–small-cell lung cancer and bladder cancer.

Imfinzi is an intravenous (IV) injection made by AstraZeneca. For treatment access and financial support, they offer the AstraZeneca Access 360 program to help you get started with Imfinzi treatment. For more information, call 1-844-ASK-A360 (1-844-275-2360), Monday-Friday, 8 am - 8 pm, or visit www.MyAccess360.com.

AstraZeneca also offers the Lighthouse program to provide support during your Imfinzi treatment with help from medically trained advocates. For more information, ask your oncology team, or call 1-855-LHOUSE1 (1-855-546-8731).

To learn more about Imfinzi and to access additional resources, you can visit www.imfinzi.com.

Opdivo (op-DEE-voh) plus Yervoy (yur-voi)

A treatment combination containing the immunotherapy drugs Opdivo and Yervoy received 2 approvals in non–small-cell lung cancer (NSCLC) in the past year. First, the drug combination was approved for the first-line treatment of metastatic NSCLC expressing PD-L1 as determined by an FDA-approved test, and no EGFR or ALK genomic tumor aberrations. Days later, the combination was approved, when given with 2 cycles of chemotherapy, for the first-line treatment of patients with advanced-stage NSCLC and whose tumors do not have an abnormal EGFR or ALK gene.

Opdivo + Yervoy is approved as a first-line treatment for adults who have lung cancer that has spread or grown (metastatic) or come back (recurrent). This drug combination, also known by their generic names nivolumab and ipilimumab, has been previously approved to treat special types of melanoma, advanced kidney cancer, and metastatic colorectal cancer that progressed after chemotherapy.

Opdivo plus Yervoy also received approval in 2020 to treat liver cancer (hepatocellular carcinoma).

Bristol Myers Squibb, the maker of both of these drugs, offers the BMS Access Support program, which provides resources to help patients understand their insurance coverage and find information on sources of financial support, including copay assistance for eligible commercially insured patients. For more information, ask your doctor, visit www.bmsaccesssupport.com, or call BMS Access Support at 1-800-861-0048, Monday-Friday, 8 am - 8 pm ET.

On the website for Opdivo, you will also find helpful patient and caregiver support materials, such as a pocket guide for Opdivo + Yervoy and a side effect tracker. For this and more resources, visit www.opdivo.com.

Retevmo (reh-TEHV-moh)

Retevmo, also known by its generic name selpercatinib, is an FDA-approved oral targeted therapy. Retevmo is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in adults with non–small-cell lung cancer (NSCLC) that has spread.

Retevmo also received FDA approval to treat certain types of thyroid cancer.

Lilly Oncology offers Savings and Support programs by way of the Retevmo Savings Card and the Retevmo Ongoing Support program. If you have questions about Retevmo, you can sign up to connect with a dedicated Companion in Care representative who can provide personalized phone support throughout your treatment. You can enroll in these programs by visiting www.retevmo.com, calling the Lilly Oncology Support Center at 1-866-472-8663, or asking a member of your healthcare team about signing up.

Tabrecta (ta-brek-tah)

Tabrecta is used to treat adults with non–small-cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery and whose tumors have an abnormality in their MET gene. Your doctor will determine if you have the MET gene mutation by using an FDA-approved test.

Tabrecta is an oral medication made by Novartis. It is also known by the generic name capmatinib. Novartis offers financial support through the Novartis Patient Navigator Program, the Patient Assistance Now Oncology (PANO) program, and the Novartis Oncology Universal Co-pay Program.

The Novartis Patient Navigator Program is staffed by a team of specialists who are available to support you during your treatment journey. Once enrolled in the program, you will receive a series of phone calls from a specially trained navigator who will help you get started on your Novartis medicine. To learn more about the Patient Navigator Program and enroll, contact PANO at 1-800-282-7630.

The PANO program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center. To learn more, call 1-800-282-7630 or visit Patient.NovartisOncology.com.

You may be eligible for immediate copay savings on your Tabrecta prescription. To find out if you are eligible for the Novartis Oncology Universal Co-pay Program, call 1-877-577-7756 or visit Copay.NovartisOncology.com.

To learn more about Tabrecta, visit www.us.tabrecta.com.

Tagrisso (tuh-GRISS-oh)

Tagrisso is a prescription medication used to treat adults with non–small-cell lung cancer that has certain abnormal epidermal growth factor receptor (EGFR) gene(s). In December 2020, the FDA approved Tagrisso to help prevent lung cancer from coming back (relapse) after the tumor has been removed by surgery. Tagrisso, also know by its generic name osimertinib, was previously approved to treat lung cancer that has spread to other parts of the body (metastatic).

AstraZeneca, the maker of Tagrisso, offers a guide to understanding Tagrisso in multiple languages, including English, Chinese, Filipino, Japanese, Korean, Spanish, and Vietnamese. On the Tagrisso website, they also offer a free information kit on diagnosis and treatment as well an invitation to connect with the Tagrisso Facebook community. For these offerings and more, please visit www.tagrisso.com.

Tecentriq (te-sen-trik)

Tecentriq is a prescription medicine used to treat adults with a type of lung cancer called non–small-cell lung cancer (NSCLC). It was approved in May 2020 to be used alone as your first treatment when the lung cancer has spread or grown and the cancer tests positive for “high PD-L1,” and the tumor does not have an abnormal EGFR or ALK gene.

Tecentriq, also known by its generic name atezolizumab, is made by Genentech and is given to patients through an intravenous (IV) infusion. On the Tecentriq website, Genentech offers a patient assistance tool to help you find out which financial assistance option might be right for you. You will also find tips for preparing for potential side effects and making the most of your doctor visits. To learn more, visit www.tecentriq.com.

Zepzelca (zep-zel’-kah)

Zepzelca, also known by its generic name lurbinectedin, is a prescription medicine used to treat adults with a kind of lung cancer called small-cell lung cancer (SCLC). Zepzelca may be used when the lung cancer has spread to other parts of the body (metastatic) and you have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.

Zepzelca is given by an intravenous (IV) injection and is also known by its generic name lurbinectedin. Patient support and access is offered by Jazz Pharmaceuticals through their JazzCares program. To learn more about JazzCares support and offerings, you can call 1-833-533-JAZZ (5299) Monday-Friday, 8 am - 8 pm ET.

To learn more about Zepzelca, please visit www.zepzelca.com.

Melanoma

Tecentriq (te-sen-trik)

Tecentriq is a prescription medicine used in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation–positive unresectable or metastatic melanoma. It recently received additional approvals to treat liver cancer and non–small-cell lung cancer (NSCLC).

Tecentriq has been previously approved to treat several types of cancer, including NSCLC, small-cell lung cancer, urothelial cancer, and triple-negative breast cancer.

Tecentriq, also known by its generic name atezolizumab, is made by Genentech and is given to patients through an intravenous (IV) infusion. On the Tecentriq website, Genentech offers a patient assistance tool to help you find out which financial assistance option might be right for you. You will also find tips for preparing for potential side effects and making the most of your doctor visits. To learn more, visit www.tecentriq.com.

Mesothelioma

Opdivo (op-DEE-voh) plus Yervoy (yur-voi)

A treatment combination containing the immunotherapy drugs Opdivo and Yervoy received approval as first-line treatment for adult patients with unresectable malignant pleural mesothelioma.

The drug combination, also known by their generic names nivolumab and ipilimumab, has been previously approved to treat special types of melanoma, advanced kidney cancer, and metastatic colorectal cancer that progressed after chemotherapy.

Opdivo plus Yervoy also received approval in 2020 for the treatment of liver cancer (hepatocellular carcinoma) and non–small-cell lung cancer.

Bristol Myers Squibb, the maker of both of these drugs, offers the BMS Access Support program, which provides resources to help patients understand their insurance coverage and find information on sources of financial support, including copay assistance for eligible commercially insured patients. For more information, ask your doctor, visit www.bmsaccesssupport.com, or call BMS Access Support at 1-800-861-0048, Monday-Friday, 8 am - 8 pm ET.

On the website for Opdivo, you will also find helpful patient and caregiver support materials, such as a pocket guide for Opdivo + Yervoy and a side effect tracker. For this and more resources, visit www.opdivo.com.

Multiple Myeloma

Blenrep (blen-rep)

Blenrep is a prescription medicine used to treat adults with multiple myeloma who have received at least 4 prior medicines, and their cancer has come back or did not respond to prior treatment. Blenrep is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Blenrep REMS. Patients who are prescribed Blenrep must be enrolled in the Blenrep REMS safety program to manage the risk of ocular toxicity.

Blenrep is also known by its generic name belantamab mafodotin-blmf and is given to patients as an intravenous (IV) infusion into your vein over approximately 30 minutes.

Blenrep is made by GlaxoSmithKline, which offers the Together with GSK Oncology patient support program. Through this program, you will find a variety of access and reimbursement resources. To learn more about this program, you can call 1-844-4GSK-ONC (1-844-447-5662), Monday-Friday, 8 am - 8 pm ET, or visit www.togetherwithgskoncology.com.

To learn more about Blenrep, visit www.blenrep.com.

Darzalex Faspro (dar-zah-lex-fas-pro)

Darzalex Faspro is a prescription medicine used to treat adults with multiple myeloma who are newly diagnosed and are unable to receive a transplant. It may also be used if you have tried other medicines. It can be used with other medicines to treat your disease or by itself.

Darzalex Faspro, also known by its generic name daratumumab and hyaluronidase-fihj, is given to patients as a subcutaneous injection (injected under the skin) and is made by Janssen Oncology. Once you and your doctor have decided that Darzalex Faspro is right for you, the Janssen CarePath program will help you find the resources you may need to get started and stay on track. You can call a Janssen CarePath Coordinator today at 1-844-55DARZA (1-844-553-2792), Monday-Friday, 8 am - 8 pm ET, create a Janssen CarePath Account at www.MyJanssenCarePath.com, or visit www.JanssenCarePath.com/darzalex/faspro.

To learn more about Darzalex Faspro and access additional patient resources, you can visit www.darzalex.com.

Kyprolis and Darzalex (kai-pro-lis and dar-zah-lex)

On August 20, 2020, the FDA approved Kyprolis and Darzalex, also known by their generic names carfilzomib and daratumumab, respectively, in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 lines of therapy.

Amgen, the maker of Kyprolis, offers the Amgen Assist 360 Nurse Ambassador program for patients, their caregivers, and anyone interested in learning more about Kyprolis. To learn more, visit www.kyprolis.com.

Janssen, the maker of Darzalex, offers the Janssen CarePath program to help you find the resources you may need to get started and stay on track. You can call a Janssen CarePath Coordinator today at 1-844-55DARZA (1-844-553-2792), Monday-Friday, 8 am - 8 pm ET, and create a Janssen CarePath Account at www.MyJanssenCarePath.com. To learn more about Darzalex and to access additional patient resources, you can visit www.darzalex.com.

Sarclisa (sar-cli-sa)

Sarclisa, also known by its generic name isatuximab-irfc, is a prescription medicine used in combination with pomalidomide and dexamethasone to treat adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma. Patients receive Sarclisa through an intravenous (IV) injection.

You can find helpful resources and support by visiting www.sarclisa.com. They offer resources to help guide and support you—whether you are considering treatment or have already begun treatment with Sarclisa. On their site, you will find a guide to Sarclisa, the Sarclisa Conversation Starter, a guide to talking with your healthcare team, as well as information on the CareASSIST Patient Support Program. Once you are enrolled in the CareASSIST program, a Patient Access Specialist can determine if there are independent support services available to you.

Xpovio (x-PO-vee-O)

Xpovio, also known by its generic name selinexor, is an oral prescription medicine used in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy. It was also recently approved to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL).

Karyopharm Therapeutics, the maker of Xpovio, offers the KaryForward patient support program that provides assistance and resources to patients and caregivers. From insurance coverage and financial assistance to support and resources, KaryForward will help you every step of the way. To get started, download an enrollment form at www.karyforward.com, or call 1-877-KARY4WD (1-877-527-9493), Monday-Friday, 8 am - 8 pm ET.

To learn more, please visit www.xpovio.com.

Myelodysplastic Syndrome

Inqovi (in-koe-vee)

Inqovi is a prescription medicine used to treat adults with myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia. Inqovi, also know by its generic names decitabine and cedazuridine, is an oral tablet you can take at home.

Inqovi is made by Otsuka Pharmaceuticals and distributed by Taiho Oncology, Inc. Taiho Oncology offers the Taiho Oncology Patient Support Program—an online and on-call resource center for any questions or needs related to financial assistance, reimbursement, and your treatment with Inqovi.

A diagnosis of MDS can be overwhelming and confusing, but the Taiho Oncology Patient Support program can help simplify your access to treatment. Visit www.TaihoPatientSupport.com to find support or call 1-844-TAIHO-4U (1-844-824-4648), Monday-Friday, 8 am - 8 pm ET.

To learn more about Inqovi, visit www.inqovi.com.

Neuroblastoma

Danyelza (dan-yel-zah)

Danyelza is the first and only prescription medicine used in combination with a medicine called GM-CSF specifically to treat children 1 year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that has come back (relapsed) or that did not respond to previous treatment (refractory) and has shown a partial response, minor response, or stable disease to prior therapy.

Danyelza, also known by its generic name naxitamab-gqgk, is given through an intravenous (IV) line over a minimum of 30 to 60 minutes.

Danyelza is made by Y-mAbs Therapeutics, Inc., which offers the Y-mAbs Connect patient support program, Y-mAbs Connect provides answers to questions related to access, insurance, financial support, and other resource programs for qualifying patients. To learn more about the Y-mAbs Connect program, visit www.ymabsconnect.com or call a case manager at 1-833-33YMABS (1-833-339-6227, option 2), Monday-Friday, 8 am - 8 pm ET.

To learn more about Danyelza, visit www.danyelza.com.

Ovarian Cancer

Lynparza (lin-par-zah)

Lynparza is a prescription medicine used to treat adults who have advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. Lynparza is used in combination with another anticancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Lynparza is right for you.

Lynparza is also known by its generic name, olaparib. The maker of Lynparza, AstraZeneca, offers patient support through its AstraZeneca Access 360 program. They can answer your questions about insurance coverage, out-of-pocket costs, and patient assistance programs. To learn more about the Access 360 program you can call 1-844-ASK-A360 (1-844-275-2360), Monday-Friday, 8 am - 8 pm ET, or visit www.MyAccess360.com.

You can also speak with one of their specially trained nurses on their support hotline by calling 1-800-770-8337.

To learn more about Lynparza, visit www.lynparza.com.

Zejula (zuh-joo-luh)

Zejula is a prescription medicine used for the maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Zejula is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.

Zejula is also known by its generic name, niraparib. It has been previously approved for the treatment of recurrent ovarian cancer in women who have had a response to platinum-based chemotherapy. Zejula is an oral medication made by GlaxoSmithKline.

GlaxoSmithKline offers Together with GSK Oncology, a support program for you and your doctor to help with access issues related to Zejula. Learn more about this program by visiting www.togetherwithgskoncology.com or call 1-844-4GSK-ONC (1-844-447-5662), Monday-Friday, 8 am - 8 pm ET.

They also offer the Zejula My Way program that provides timely support delivered to your inbox and your mailbox. To learn more about Zejula and patient support programs, visit www.zejula.com.

Prostate Cancer

Lynparza (lin-par-zuh)

Lynparza is for men with HRR gene mutations whose prostate cancer has spread to other parts of the body, no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure Lynparza is right for you.

Lynparza is not hormone therapy or chemotherapy. It’s an oral medication—2 tablets, twice a day—that you can take with you wherever you go.

Lynparza is also known by its generic name, olaparib. The maker of Lynparza, AstraZeneca, offers patient support through its AstraZeneca Access 360 program. They can answer your questions about insurance coverage, out-of-pocket costs, and patient assistance programs. To learn more about the Access 360 program you can call 1-844-ASK-A360 (1-844-275-2360), Monday-Friday, 8 am - 8 pm ET, or visit www.MyAccess360.com.

You can also speak with one of their specially trained nurses on their support hotline by calling 1-800-770-8337.

To learn more about Lynparza, visit www.lynparza.com.

Orgovyx (or-GO-vix)

Orgovyx is a prescription medicine used in adults for the treatment of advanced prostate cancer. Orgovyx, also known by its generic name relugolix, is the only androgen deprivation therapy (ADT) medicine that is given by oral tablet, not an injection.

Myovant Sciences, the maker of Orgovyx, offers the Orgovyx Support Program, which provides one-on-one support to make your start on Orgovyx as simple as possible and provides tools and resources to support you throughout treatment.

To learn more, visit www.orgovyx.com or call 1-833-ORGOVYX (1-833-674-6899), Monday-Friday, 8 am - 8 pm ET.

Rubraca (roo-brah-kah)

Rubraca tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone) that has spread to other parts of the body and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.

Rubraca is also known by its generic name, rucaparib. It is made by Clovis Oncology, which offers the Rubraca Connections program. To speak to a live Rubraca Connections Access Specialist who can help you with questions about financial support on receiving your medication, call 1-844-779-7707, Monday-Friday, 8 am - 8 pm ET, or visit www.rubracaconnections.com.

To learn more about Rubraca visit www.rubraca.com/prostate-cancer.

Sarcoma

Tazverik (taz-vayr-ik)

Tazverik is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

Tazverik is also known by its generic name tazemetostat. It has been previously approved to treat certain types of lymphoma. Tazverik is made by Epizyme, which offers EpizymeNOW Patient & Product Support programs. EpizymeNOW offers a Quick Start Program, the Bridge Supply Program, the Patient Assistance Program, and the Co-Pay Assistance Program. To learn more about these services, ask your doctor or contact EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday-Friday, 9 am - 6 pm ET.

To learn more about Tazverik, please visit www.tazverik.com.

Thyroid Cancer

Gavreto (gav-reh-toh)

Gavreto is a prescription medicine used to treat patients with RET-positive advanced thyroid cancer. Gavreto also recently received FDA approval to treat adult patients with non–small-cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) and is caused by abnormal RET genes.

To see if your thyroid cancer is RET-positive, your doctor will need to perform a type of test called a biomarker test. A biomarker test can help your doctor decide if Gavreto could be right for you.

Gavreto, also known by its generic name pralsetinib, is a once-daily oral prescription medicine.

The maker of Gavreto, Blueprint Medicines, offers the YourBlueprint patient support program. This program is designed to assist you throughout your treatment with Gavreto by providing financial assistance, temporary treatment programs, and a dedicated case manager. Learn more about the YourBlueprint program by calling 1-888-BLUPRNT (1-888-258-7768) or visiting www.YourBlueprint.com.

To learn more about Gavreto, visit www.gavreto.com.

Retevmo (reh-TEHV-moh)

Retevmo, also known by its generic name selpercatinib, is an FDA-approved oral targeted therapy. Retevmo is a prescription medicine that is used to treat adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy), and adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.

Lilly Oncology offers Savings and Support programs by way of the Retevmo Savings Card and the Retevmo Ongoing Support program. If you have questions about Retevmo, you can sign up to connect with a dedicated Companion in Care representative who can provide personalized phone support throughout your treatment. You can enroll in this program by visiting www.retevmo.com, calling the Lilly Oncology Support Center at 1-866-472-8663, or asking a member of your healthcare team about signing up.

Urothelial Cancer

Bavencio (buh-VEN-see-oh)

Bavencio is a prescription medicine recently approved by the FDA for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has responded or stabilized after platinum-containing chemotherapy as first-line treatment. Bavencio, also known by its generic name avelumab, has previously been approved to treat a type of skin cancer called Merkel cell carcinoma, urothelial carcinoma, and a type of kidney cancer called renal-cell carcinoma.

CoverOne provides patient access and reimbursement support to help eligible patients gain appropriate access to Bavencio. To learn more about CoverOne, please visit www.CoverOne.com or call 1-844-8COVER1 (1-844-826-8371), Monday-Friday, 8 am - 8 pm ET.

To learn more about Bavencio, visit www.bavencio.com.

Jelmyto (jel-mye-toe)

Jelmyto is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract, including the kidney, called low-grade upper tract urothelial cancer.

Jelmyto is given directly where the tumor is and stays there for up to 4 to 6 hours to kill cancer cells. You will receive Jelmyto through a thin flexible tube, called a catheter, once weekly for 6 weeks in an office, hospital, or other outpatient setting.

Jelmyto is also known by its generic name, mitomycin. It is made by UroGen. Patient affordability resources as well as other useful information about treatment with Jelmyto can be found at www.jelmyto.com.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma. Ukoniq is used for MZL after 1 or more anti-CD20 therapies, and for follicular lymphoma after 3 or more lines of systemic therapy. Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta First Gene Therapy Approved for Follicular Lymphoma
In March 2021, the FDA approved a new indication for Yescarta (axicabtagene ciloleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of patients with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
In March 2021, the FDA approved Abecma (idecabtagene vicleucel; from Bristol Myers Squibb/Bluebird Bio), a BCMA-directed, genetically modified CAR T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or returned, after 4 or more lines of therapy. Abecma is the first gene therapy approved by the FDA for the treatment of multiple myeloma.
Last modified: February 12, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country